Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

Journal of the National Cancer Institute

Volumn 98, Issue 23, 2006, Pages 1739-1742

  Cusatis, George ^a   Gregorc, Vanesa ^b   Li, Jing ^a   Spreafico, Anna ^b   Ingersoll, Roxann G ^d   Verweij, Jaap ^e   Ludovini, Vienna ^c   Villa, Eugenio ^b   Hidalgo, Manuel ^a   Sparreboom, Alex ^f   Baker, Sharyn D ^a,g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Obstetrics and Gynaecology Department   (Italy)

^c POLICLINICO MONTELUCE   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f NATIONAL CANCER INSTITUTE   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ALLELE; AMINO ACID SEQUENCE; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; FEMALE; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; WILD TYPE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DIARRHEA; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, GENETIC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; VARIATION (GENETICS);

EID: 33845657889     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj469     Document Type: Article

References (26)

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.
2. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-58.
3. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780-5.
4. Razis E, Skarlos D, Briasoulis E, Dimopoulos M, Fountzilas G, Lambropoulos S, et al. Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): The Greek experience with a compassionate-use program. Anticancer Drugs 2005;16:191-8.
5. Schutte W, Nagel S, Schaedlich S, Brust D, Blankenburg T. Clinical benefit in NSCLC: Advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. Onkologie 2005;28:195-8.
6. Li J, Karlsson MO, Brahmer J, Cusatis G, Hidalgo M, Baker SD. Population pharmacokinetic (PK)-pharmacodynamic (PD) modelfor gefitinib in cancer patients. Proc Am Soc Clin Oncol 2005;41:ABstract 3083.
7. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: Is there a silver lining? J Clin Oncol 2005; 23:5235-46.
8. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: The role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005;6: 115-38.
9. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005;65:1770-7.
10. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 2004;64:7491-9.
11. , ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65:1541-6.
12. Li J, Sparreboom A, Zhao M, Robey RW, Bates SE, Baker SD. Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, are substrates for the breast cancer resistance protein (BCRP)/ABCG2 transporter. Clin Cancer Res 2005;115:120 (Abstract A251).
13. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-95.
14. Gardner ER, Figg WD, Sparreboom A. Pharmacogenomics of the human ATP-binding cassette transporter ABCG2. Curr Pharmacogenomics. 2006;4:iN press.
15. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1:611-6.
16. Song P, Lamba JK, Zhang L, Schuetz E, Shukla N, Meibohm B, et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 2006;46:373-9.
17. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005;15:693-704.
18. Johnson BE, Janne PA. Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? J Clin Oncol 2005;23:6813-6.
19. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
20. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854-7.
21. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-80.
22. Liu W, Innocenti F, Wu NM, Desai AA, Dolan ME, Cook EH Jr, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65:46-53.
23. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-43.
24. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10(Pt 1):6006-12.
25. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104: 2940-2.
26. Hintze J. NCSS and PASS. Number Cruncher Statistical Systems. Kaysville (UT); 2004. Available at: http://www.ncss.com. [Last accessed: October 27, 2006.]